Educational theme | Latest advances in the treatment for patients with Hodgkin lymphoma

We highlight the latest advances in the treatment of HL presented at the European Hematology Association (EHA)...

Emerging novel therapies for the treatment of patients with aggressive R/R NHL

Despite the success of chimeric antigen receptor (CAR) T-cell therapies in patients with relapsed/refractory (R/R)...

Phase I data of golidocitinib for R/R peripheral T-cell lymphoma: JACKPOT8 trial

The study met its primary endpoint, elucidating the adverse events associated with golidocitinib in patients with R/R...

Is peripheral neuropathy in patients with DLBCL more severe after pola-R-CHP vs R-CHOP treatment?

During the EHA 2022 Congress, the Lymphoma Hub spoke with Marek Trněný, Charles University, Prague,...

What are the latest treatment advances for Hodgkin lymphoma?

During the 2022 ASCO Annual Meeting, the Lymphoma Hub spoke with Alison Moskowitz, Feinstein Institutes for Medical Research, New York, US....

What is on the horizon for the frontline treatment of MCL?

During the ASCO 2022 congress, the Lymphoma Hub was pleased to speak with Anita Kumar, Memorial Sloane Kettering Cancer Center, New York,...

Latest advances in the treatment of mantle cell lymphoma

The current and future treatment landscape for MCL looks hopeful, with the development of new treatment regimens and novel therapeutics that...

CAPTIVATE 3-year update: fixed-duration ibrutinib + venetoclax in CLL/SLL

The 3-year follow-up of the FD cohort showed that I + V continues to demonstrate deep and durable responses, with a clinically...

Responses to the SARS-CoV-2 booster vaccination in patients with lymphoid malignancies

Here, we provide a summary of two papers investigating humoral and T-cell-mediated responses in patients with...

How do CAR T-cell recipients respond to COVID-19 vaccination?

During the 4th European CAR T-Cell Meeting, the Lymphoma Hub was pleased to speak to Arnon Nagler, Sheba Medical Center, Tel Aviv, IL. We...

COVID-19 severity, mortality, and mRNA vaccine responses in patients with CLL

Since the first cases of coronavirus disease 2019 (COVID-19) were reported in December 2019, more than 3 million people...

Humoral and cellular responses in patients with lymphoid malignancies receiving SARS-Cov-2 vaccination

Factors that influence the efficacy of Severe Acute Respiratory Syndrome Coronavirus-2...

Visual abstract | A safety, efficacy and pharmacokinetic study of mosunetuzumab in non-Hodgkin lymphoma

The Lymphoma hub is happy to present a visual abstract representing key data from a phase 1...

Resource-stratified guidelines for the management of classical Hodgkin lymphoma

A visual abstract summarizing resource-stratified guidelines for the management of classical Hodgkin lymphoma. Existing...

Visual abstract | Key data from the phase I trial ELM-1, evaluating odronextamab in patients with CD20+ B-cell malignancies

The Lymphoma Hub is happy to present a visual abstract representing key...

Axi-cel vs SoC for R/R LBCL: ZUMA-7 primary analysis

The Lymphoma Hub is happy to present a Visual Abstract representing key data from the primary analysis of the phase III ZUMA-7 study (NCT03391466),...